上海崇明地区3家二级综合医院2011-2013年抗菌药物类国家基本药物使用情况分析

Utilization Analysis of National Essential Medicines in Antibiotics in 3 Second-level General Hospitals from Chongming Area of Shanghai from 2011 to 2013

目的:为促进抗菌药物类国家基本药物的合理使用提供参考。方法:对上海崇明地区3家二级综合医院2011-2013年抗菌药物类国家基本药物的使用情况进行统计、分析。结果:抗菌药物类国家基本药物销售金额呈增长趋势,年平均增长率为28.16%;而其销售金额占药品销售总金额比例仍较低,平均为2.16%。2011-2013年排序列前3位的3类抗菌药物销售金额之和分别占抗菌药物类国家基本药物销售总金额的87.92%、93.60%、95.54%,呈上升趋势;而抗菌药物类国家基本药物DDDs 2012、2013年较2011年有所下降。DDDs排序列前2位的是头孢呋辛酯片、阿莫西林胶囊,销售金额居首位的是注射用头孢呋辛钠;金额/DDDs排序比接近1的品种较少,说明用药金额与用药人次同步性较差。结论:抗菌药物类国家基本药物应用仍存在一些问题,在以后的相关工作中需持续改进,进一步提高用药合理性和经济性,逐步实现抗菌药物临床应用管理的制度化、常态化。

OBJECTIVE：To provide reference for promoting the rational use of national essential medicines in antibiotics.METHODS：The use of national essential drugs in antibiotics in 3 second-level general hospitals from Chongming area of Shanghai from 2011 to 2013 were statistically analyzed. RESULTS：The sales amount of antibiotics was in an increasing trend,with an average growth rate of 28.16%;while the proportion of sales amount accounted for the total sales amount of drugs were still relatively low,with an average growth rate of 2.16%. The proportion of total sales amount of top 3 antibiotics from 2011 to 2013 accounted for the total sales amount of drugs were respectively 87.92%,93.60% and 95.54%,with an increasing trend;while compared with 2011,the DDDs of national essential medicines in antibiotics was decreased a little during 2012-2013;the top 2 DDDs were Cefuroxime axetil tablets and Amoxicillin capsules,the top 1 sales amount was Cefuroxime sodium for injection. Varieties with the sales amount / DDDs close to 1 were relatively less,indicating that the sales amount of drugs and the number of drug use was not synchronous. CONCLUSIONS：There are still some problems in the utilization of national essential medicines in antibiotics. It needs to be continuously improved in the related work to further improve medication rationality and economy,and progressively realize the institutionalized and normalized antibiotics in clinical use management.